华东医药：罗氟司特乳膏上市许可申请获受理

Core Viewpoint - Huadong Medicine (000963) announced that its wholly-owned subsidiary, Sino-American Huadong, received the Acceptance Notice from the National Medical Products Administration for the marketing application of ZORYVE® (0.15% Roflumilast Cream), which is intended for local treatment of mild to moderate atopic dermatitis in patients aged 6 and above [1] Group 1 - The marketing application for Roflumilast Cream has been accepted, indicating progress in the drug approval process [1] - The drug is specifically designed for local treatment of atopic dermatitis, targeting a significant patient demographic [1] - The acceptance by the National Medical Products Administration is a crucial step towards commercialization [1]